Cargando…
Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers
The formation of oligomers of the amyloid-β peptide plays a key role in the onset of Alzheimer's disease. We describe herein the investigation of disease-relevant small amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing functionally relevant structural attributes....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682991/ https://www.ncbi.nlm.nih.gov/pubmed/33095161 http://dx.doi.org/10.7554/eLife.59306 |
_version_ | 1783612788144340992 |
---|---|
author | Lieblein, Tobias Zangl, Rene Martin, Janosch Hoffmann, Jan Hutchison, Marie J Stark, Tina Stirnal, Elke Schrader, Thomas Schwalbe, Harald Morgner, Nina |
author_facet | Lieblein, Tobias Zangl, Rene Martin, Janosch Hoffmann, Jan Hutchison, Marie J Stark, Tina Stirnal, Elke Schrader, Thomas Schwalbe, Harald Morgner, Nina |
author_sort | Lieblein, Tobias |
collection | PubMed |
description | The formation of oligomers of the amyloid-β peptide plays a key role in the onset of Alzheimer's disease. We describe herein the investigation of disease-relevant small amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing functionally relevant structural attributes. In particular, we can show that amyloid-β oligomers develop in two distinct arrangements leading to either neurotoxic oligomers and fibrils or non-toxic amorphous aggregates. Comprehending the key-attributes responsible for those pathways on a molecular level is a pre-requisite to specifically target the peptide's tertiary structure with the aim to promote the emergence of non-toxic aggregates. Here, we show for two fibril inhibiting ligands, an ionic molecular tweezer and a hydrophobic peptide that despite their different interaction mechanisms, the suppression of the fibril pathway can be deduced from the disappearance of the corresponding structure of the first amyloid-β oligomers. |
format | Online Article Text |
id | pubmed-7682991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-76829912020-11-25 Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers Lieblein, Tobias Zangl, Rene Martin, Janosch Hoffmann, Jan Hutchison, Marie J Stark, Tina Stirnal, Elke Schrader, Thomas Schwalbe, Harald Morgner, Nina eLife Neuroscience The formation of oligomers of the amyloid-β peptide plays a key role in the onset of Alzheimer's disease. We describe herein the investigation of disease-relevant small amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing functionally relevant structural attributes. In particular, we can show that amyloid-β oligomers develop in two distinct arrangements leading to either neurotoxic oligomers and fibrils or non-toxic amorphous aggregates. Comprehending the key-attributes responsible for those pathways on a molecular level is a pre-requisite to specifically target the peptide's tertiary structure with the aim to promote the emergence of non-toxic aggregates. Here, we show for two fibril inhibiting ligands, an ionic molecular tweezer and a hydrophobic peptide that despite their different interaction mechanisms, the suppression of the fibril pathway can be deduced from the disappearance of the corresponding structure of the first amyloid-β oligomers. eLife Sciences Publications, Ltd 2020-10-23 /pmc/articles/PMC7682991/ /pubmed/33095161 http://dx.doi.org/10.7554/eLife.59306 Text en © 2020, Lieblein et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Neuroscience Lieblein, Tobias Zangl, Rene Martin, Janosch Hoffmann, Jan Hutchison, Marie J Stark, Tina Stirnal, Elke Schrader, Thomas Schwalbe, Harald Morgner, Nina Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers |
title | Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers |
title_full | Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers |
title_fullStr | Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers |
title_full_unstemmed | Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers |
title_short | Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers |
title_sort | structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of alzheimer’s disease related oligomers |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682991/ https://www.ncbi.nlm.nih.gov/pubmed/33095161 http://dx.doi.org/10.7554/eLife.59306 |
work_keys_str_mv | AT liebleintobias structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT zanglrene structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT martinjanosch structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT hoffmannjan structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT hutchisonmariej structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT starktina structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT stirnalelke structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT schraderthomas structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT schwalbeharald structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers AT morgnernina structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers |